Nkarta Inc
$ 3.47
23.93%
17 Apr - close price
- Market Cap 247,378,000 USD
- Current Price $ 3.47
- High / Low $ 3.48 / 2.79
- Stock P/E N/A
- Book Value 4.39
- EPS -1.41
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.29 %
- 52 Week High 3.48
- 52 Week Low 1.63
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Analyst Target Price
$14.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-05 | 2025-08-12 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.37 | -0.29 | -0.31 | -0.43 | -0.35 | -0.39 | -0.34 | -0.58 | -0.57 | -0.52 | -0.6 | -0.63 |
| Estimated EPS | -0.295 | -0.338 | -0.35 | -0.45 | -0.4 | -0.36 | -0.45 | -0.56 | -0.59 | -0.67 | -0.68 | -0.7 |
| Surprise | -0.075 | 0.048 | 0.04 | 0.02 | 0.05 | -0.03 | 0.11 | -0.02 | 0.02 | 0.15 | 0.08 | 0.07 |
| Surprise Percentage | -25.4237% | 14.2012% | 11.4286% | 4.4444% | 12.5% | -8.3333% | 24.4444% | -3.5714% | 3.3898% | 22.3881% | 11.7647% | 10% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTX
2026-04-16 21:40:44
Stifel has reiterated its Buy rating on Nkarta (NKTX.US) and maintained a target price of $11. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.
2026-04-16 13:39:31
Needham has reaffirmed its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects. Investors may view this sustained recommendation as a positive signal for Nkarta's stock.
2026-04-15 19:39:20
Nkarta has reached an agreement with the FDA to amend protocols for its Ntrust-1 and Ntrust-2 clinical trials, allowing for outpatient dosing of NKX019 and reducing post-dose monitoring from 24 hours to 2 hours. This change aims to reduce patient burden and expand access to community rheumatology centers. The amendments also include an option to re-dose participants and will add a rheumatoid arthritis cohort to Ntrust-2, with initial data expected this year.
2026-04-15 19:39:20
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials, allowing outpatient administration of NKX019 and reducing patient burden. This amendment will also enable the addition of a rheumatoid arthritis cohort to the Ntrust-2 study and allow for re-dosing of patients. These changes aim to expand access to community rheumatology centers and optimize treatment responses.
2026-04-09 17:39:14
Nkarta, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on "Cell Therapy in Autoimmune: State of the Art and What Comes Next," and President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's investor website.
2026-04-09 17:09:43
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will lead a fireside chat discussing updates on the company's investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's website.
